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Abstract. The aims of radiotherapeutic treatment of brain 
metastases include maintaining neurocognitive function and 
improvement of survival. Based on these premises, we present 
a case report in which the role of repeat stereotactic radiosur-
gery (SRS) was investigated in a patient with a recurrent brain 
metastasis from non-small cell lung cancer in the same area 
as previously treated with radiosurgery. A 40-year-old male 
caucasian patient was diagnosed with brain metastasis from 
non-small cell lung cancer (NSCLC) and underwent SRS. The 
patient developed a recurrence of the disease and a second 
SRS on the same area was performed. After 8 months, tumor 
restaging demonstrated a lesion compatible with a recurrence 
and the patient underwent surgery. Histological diagnosis 
following surgery revealed only the occurrence of radione-
crosis. Radiotherapy was well-tolerated and no grade 3/4 
neurological toxicity occurred. To date, no consensus exists 
on the efficacy of retreatment with SRS. Despite the limited 
number of studies in this field, in the present case report, we 
outline the outcomes of this unconventional approach.
Introduction
Non-small cell lung cancer (NSCLC) is the leading cause 
of mortality from cancer and the most common source of 
brain metastases. It is estimated that between 30 and 50% 
of lung cancer patients develop metastatic cancer to the 
brain during the course of their illness (1). Patients with 
untreated brain metastases have a median survival time of 
~4 weeks and almost all succumb to neurological rather than 
systemic causes (2). Management and treatment of metastatic 
brain tumors are complex and dependent on several factors, 
including age, performance status, number of metastases at 
presentation and status of systemic disease. Radiation therapy 
options for brain metastases include whole brain radiotherapy 
(WBRT) and stereotactic radiosurgery (SRS). For a number 
of years, WBRT has been the primary brain metastases 
treatment; however, a number of studies have reported an 
unfavorable effect on neurocognitive function which, in turn, 
correlates with decreased quality of life (3,4). By contrast, SRS 
alone provides great benefits in managing brain metastases, 
representing a minimally invasive treatment with an excellent 
local control rate, correlating with a minor risk of neurological 
dysfunction (5).
Repeat SRS for recurrent metastases is a noteworthy 
option, although, few clinical studies support normal brain 
tissue tolerance to re-irradiation (6,7).
In the current case report, we present a patient with brain 
metastasis of NSCLC who underwent repeat SRS, analyzing 
the outcomes (response, survival and toxicity) and the clinical 
utility, and comparing our approach with other experiences 
described in the literature.
Case report
Clinical presentation and treatment. In April 2010, a 
40-year-old male, with a history of NSCLC (histology, adeno-
carcinoma) treated from 2008, was referred to the Department 
of Radiation Oncology, Tommaso Campanella Cancer 
Center (Catanzaro, Italy) for a lesion in the right frontal lobe 
measuring 1.4 cm in maximum diameter (Fig. 1A). Based 
on RTOG criteria, the patient was eligible for SRS: Lesion 
measuring <3 cm in maximum diameter, producing minimal 
mass effect and ECOG performance status, 0.
In May 2010, the patient underwent a stereotactic treat-
ment delivered in a single dose of 24 Gy using a Clinac DBX 
600 (Varian Medical Systems Inc., Palo Alto, CA, USA) and 
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was followed up clinically by serial MRI and CT scans. In 
September 2010, a complete response to the radiotherapy 
treatment was documented by an MRI of the brain.
Disease recurrence. A CT scan revealed a recurrent disease, 
in the same area as treated previously, 17 months after the irra-
diation of the metastatic brain tumor (Fig. 1B). At this point, 
the patient was offered a second SRS treatment as an alterna-
tive to surgery. Following obtaining consent for re-irradiation, 
in November 2011, the patient underwent a second session of 
radiosurgery, which was delivered in the same manner as the 
initial session, but at a single dose of 15 Gy (Fig. 2A and B). In 
Figure 1. MRI of the brain. Right frontal lesion prior to (A) first and (B) second stereotactic radiosurgery treatment.
Figure 2. Dose distribution with 3D‑CRT plan to the brain lesion. Radiosurgery plan showing the tumor volume, and (A) 24 Gy (first treatment) and (B) 15 Gy 
(second treatment) isodose lines covering the whole tumor.
Figure 3. Histological examination following surgery. Pathological specificity of late cerebral radionecrosis with typical coagulation necrosis showed profound 
vascular changes (A), including fibrinoid necrosis and hyalinization of the wall, occlusion of lumina by fibrin thrombi with exudation of fibrinous material and 
hyaline material (B), and poorly active inflammatory areas with a number of inflammatory ghost cells (C). H&E staining; magnification, x20.
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this case, the dose was selected according to a previous study 
using the linear quadratic model to derive information on the 
cumulative biological effective tolerance dose (BEDcumulative) 
that results from BEDinitial plus BEDre-irradiation (8).
A stable disease, associated with no symptoms or signs 
associated with neurological decline, was documented in the 
following CT scan and MRI brain controls until July 2012, when 
a MRI brain scan again showed a lesion measuring 1 cm in 
diameter in the same region and surrounded by an extensive area 
of vasogenic edema, compatible with a recurrence of disease.
Therefore, in August 2012, the patient underwent surgery 
to remove the right frontal lesion. Histological diagnosis 
following surgery showed absence of disease and the occur-
rence of radionecrosis (Fig. 3A-C).
At present, the patient is receiving treatment with erlotinib 
and appears to be in good general condition (ECOG perfor-
mance status, 0).
Discussion
When we decided to repeat SRS in the current case, it was 
important to scrutinize the existing evidence available 
regarding the use of SRS for the treatment of recurrent/progres-
sive brain metastases. In this case, recurrent brain metastasis 
was defined as metastasis that has recurred at the original site 
of the brain following initial therapy.
The present patient belongs to category of individuals who 
survive long enough to experience recurrence of previously 
treated brain metastases but for whom no consensus on treat-
ment exists, as the majority of studies have focused on newly 
diagnosed patients. In addition, few studies have demonstrated 
the clinical utility of repeat SRS for brain metastases.
Ammirati et al previously reported that there is insufficient 
evidence with regard to repeat SRS to generate definitive treat-
ment recommendations in patients with recurrent/progressive 
brain metastases. Therefore, the treatment must be individual-
ized based on a patient's functional status, extent of disease, 
volume/number of metastases, recurrence or progression 
at the original site, previous treatment and type of primary 
cancer (9).
The value of SRS for recurrent brain metastases remains 
unclear and only five case studies (with Class III evidence 
according to the American Association of Neurological 
Surgeons/Congress of Neurological Surgeons criteria) (9) 
reported in the literature have demonstrated the clinical utility 
of repeat SRS and have evaluated its efficacy in patients whose 
previous treatment protocol included radiosurgery. In addition, 
only three of these case studies provide survival data from the 
date of SRS for recurrent disease. Yamanaka et al (10) and 
Shuto et al (11) reported median survival times from initial 
SRS of 15 and 22.4 months, respectively, in patients who 
repeated SRS for recurrent or newly developed brain metas-
tases from various types of malignancies.
In a previous study by Chen et al, median survival from 
the time of SRS for recurrent brain metastases was 7 months 
in 45 patients (12). In addition, in a study by Kwon et al, 
43 patients underwent salvage SRS and the median survival 
from the time of SRS for recurrent/progressive disease was 
8 months (13). More recently, Mariya et al reported that repeat 
SRS is an effective treatment option, leading to a long survival 
with a decreased neurological decline (14,15). The authors 
analyzed 28 patients who underwent salvage radiosurgery for 
recurrent brain metastases from NSCLC showing a median 
survival from initial SRS of 26 months and 11 months for 
post-repeat SRS.
In our experience, based on these previous studies, repeat 
SRS was evaluated as the most effective alternative therapy. 
In addition, our patient was included in the most favorable 
prognostic group (baseline characteristics: age, <50 years old; 
KPS 90-100; 1 intracranial metastasis present and absence of 
extracranial metastases) for the existing criteria of a prognostic 
classification called Graded Prognostic Assessment, based on 
a previous review of the RTOG database (16).
An additional advantage of repeat SRS is the possibility 
to administer precisely directed, high-dose irradiation that 
tightly conforms to an intracranial target, in order to create a 
desired radiobiological response while minimizing radiation 
dose to surrounding normal tissue. Our primary end-point was 
to preserve the neurocognitive functions of the patient, consid-
ering the high risk of neurological decline with conventional 
radiotherapy techniques (3,4).
With regard to neurological complications of repeat SRS, 
Bhatnagar et al reported that repeat SRS was performed 
with minimal CNS toxicity compared with the baseline in 
26 patients with benign and malignant tumors (17). In the 
final report of RTOG protocol 90‑05, Shaw et al revealed the 
feasibility of SRS as retreatment of recurrent primary and 
metastatic brain tumors previously irradiated. The authors 
also showed that the maximally tolerated SRS dose ranged 
between 15 and 24 Gy, depending on the tumor size (18).
In the present case study, progression-free survival was 
18 months starting from the initial radiosurgical treatment 
and 8 months from post-repeat SRS. The retreatment was well 
tolerated by the patient and no acute toxicity was observed. 
Neurological status was estimated from medical records, 
according to the criteria by Bhatnagar et al, based on the serial 
changes of 3 neurological symptoms: Seizures, focal deficits 
and headaches (17). None of these or any new symptoms were 
documented following repeat SRS. In addition, at each clinical 
control, neurological status and the severity of complica-
tions were rated according to RTOG CNS toxicity criteria as 
grade 0, according to the RTOG/EORTC scoring schema (19).
In addition, clinical chronic use of steroids was not neces-
sary. Mini-mental state examinations were performed prior to 
and soon following the first and second radiotherapy treatment, 
and every 3 months during the follow-up, identifying a stable 
score ranging between 26 and 30. Repeat SRS was performed to 
improve local brain tumor control and reduce the neurological 
decline risk, enabling the patient to return to work.
Observations of the current and previous case studies 
discussed indicate the clinical usefulness and feasibility of 
repeat SRS as salvage treatment for the management of brain 
metastases from NSCLC, and may be a valid approach for a 
selected group of patients with recurrent brain metastases.
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